DOCSLIB.ORG

An Activated Form of ADAM10 Is Tumor Selective and Regulates Cancer Stem-Like Cells and Tumor Growth

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
An Activated Form of ADAM10 Is Tumor Selective and Regulates Cancer Stem-Like Cells and Tumor Growth Published August 8, 2016 Article An activated form of ADAM10 is tumor selective and regulates cancer stem-like cells and tumor growth Lakmali Atapattu,1* Nayanendu Saha,3* Chanly Chheang,1 Moritz F. Eissman,4 Kai Xu,3 Mary E. Vail,1 Linda Hii,1 Carmen Llerena,1 Zhanqi Liu,5 Katja Horvay,2 Helen E. Abud,2 Ulrike Kusebauch,6 Robert L. Moritz,6 Bi-Sen Ding,7 Zhongwei Cao,7 Shahin Rafii,7 Matthias Ernst,4 Andrew M. Scott,5 Dimitar B. Nikolov,3 Martin Lackmann,1 and Peter W. Janes1 1Cancer Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology and 2Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria 3800, Australia 3Structural Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 4Cancer and Inflammation Laboratory and 5Tumor Targeting Laboratory, Olivia Newton-John Cancer Research Institute and School of Cancer Medicine, La Trobe University, Heidelberg, Victoria 3084, Australia 6Institute for Systems Biology, Seattle, WA 98109 7 Department of Genetic Medicine, Weill Cornell Medical College, New York, NY 10065 Downloaded from The transmembrane metalloprotease ADAM10 sheds a range of cell surface proteins, including ligands and receptors of the Notch, Eph, and erbB families, thereby activating signaling pathways critical for tumor initiation and maintenance. ADAM10 is thus a promising therapeutic target. Although widely expressed, its activity is normally tightly regulated. We now report prevalence of an active form of ADAM10 in tumors compared with normal tissues, in mouse models and humans, identified by our conformation-specific antibody mAb 8C7. Structure/function experiments indicate mAb 8C7 binds an active conformation jem.rupress.org dependent on disulfide isomerization and oxidative conditions, common in tumors. Moreover, this active ADAM10 form marks cancer stem-like cells with active Notch signaling, known to mediate chemoresistance. Importantly, specific targeting of active ADAM10 with 8C7 inhibits Notch activity and tumor growth in mouse models, particularly regrowth after chemotherapy. Our results indicate targeted inhibition of active ADAM10 as a potential therapy for ADAM10-dependent tumor development and drug resistance. on August 23, 2016 INT ROD UCT ION ADAM (a disintegrin and metalloprotease) transmembrane frequently overexpressed in cancers, correlating with aber- metalloproteases (MPs) catalyze the release of a range of cell rant signaling and poor patient prognosis, including cancers surface proteins, activating receptor tyrosine kinase (RTK), of the colon, lung, stomach, uterus, and ovary (Pruessmeyer Notch, cytokine, chemokine, and adhesion signaling path- and Ludwig, 2009). They are thus potent activators of key ways important in normal and oncogenic development. oncogenic pathways and recognized targets for multipathway Prominent oncogenic substrates include ligands and recep- inhibition (Murphy, 2008; Hartmann et al., 2013). The Journal of Experimental Medicine tors in the Notch, erbB, and Eph families, cytokines (TNF ADAM10 in particular acts as principal sheddase for and IL6), FAS ligand, Slit, L-selectin, and cadherins (Mur- Notch (Hartmann et al., 2002), Eph (Hattori et al., 2000; phy, 2008), which are all shed by one of two closely related Janes et al., 2005), and certain epidermal growth factor re- and widely expressed proteases, ADAM10 and ADAM17 (or ceptor (EGFR) ligands (Sahin et al., 2004), as well as E- and TACE [TNF converting enzyme]). These proteases are also N-cadherin (Reiss et al., 2005). The resemblance of ADAM10 and Notch-deficient mice, including embryonic defects in Dr. Lackmann died on 22 May 2014. somitogenesis, neurogenesis, and vasculogenesis (Hartmann *L. Atapattu and N. Saha contributed equally to this paper. et al., 2002; Saftig and Reiss, 2011), highlights a critical role Correspondence to Peter W. Janes: [email protected] for ADAM10 in canonical ligand-activated Notch signaling L. Atapattu’s present address is Children's Cancer Institute, Lowy Cancer Research in particular. Notch signaling is triggered by binding of cell Centre, University of New South Wales, Randwick, New South Wales 2031, Australia. surface–bound ligands, Delta-Like (1–4) or Jagged (1 and Abbreviations used: ADAM, a disintegrin and metalloprotease; CDR, complementarity 2), to Notch receptors (Notch1–4), which initiates ADAM- determining region; CRC, colorectal cancer; CSC, cancer stem cell; ECD, extracellular mediated shedding of both ligand (LaVoie and Selkoe, 2003) domain; EGFR, epidermal growth factor receptor; EMT, epithelial to mesenchymal and receptor extracellular domains (ECDs; Kopan and Ilagan, transition; GSI, γ-secretase inhibitor; HMW, high molecular weight; IF, immunofluores- cence; IHC, immunohistochemistry; IP, immunoprecipitation; LMW, low molecular weight; MMP, matrix MP; MP, metalloprotease; MPB, maleimide-PEG2-biotin; NICD, © 2016 Atapattu et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www .rupress .org notch intracellular domain; PDI, protein disulfide isomerase; ROS, reactive oxygen /terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial– species; RTK, receptor tyrosine kinase; WB, Western blot. Share Alike 3.0 Unported license, as described at http ://creativecommons .org /licenses /by -nc -sa /3 .0 /). The Rockefeller University Press $30.00 Supplemental Material can be found at: J. Exp. Med. 2016 Vol. 213 No. 9 1741–1757 http://jem.rupress.org/content/suppl/2016/07/28/jem.20151095.DC1.html 1741 www.jem.org/cgi/doi/10.1084/jem.20151095 Published August 8, 2016 2009). Shedding of the notch ECD provides the signal for which, mAb 8C7, specifically recognized the substrate-bind- γ-secretases to cleave and release the Notch intracellular do- ing C domain and inhibited ADAM10-mediated cleavage of main (NICD), acting as transcriptional activator for an exten- Eph receptor ligands (ephrins) and ephrin/Eph-dependent sive set of genes, regulating cell proliferation, differentiation, signaling and cell segregation in vitro (Atapattu et al., 2012). epithelial to mesenchymal transition (EMT), and cell sur- We thus sought to test the mechanism of action of 8C7 and its vival (Kopan and Ilagan, 2009). Deregulated Notch signaling efficacy for tumor growth inhibition. We find 8C7 specifically promotes the progression of solid cancers (Ranganathan et binds a CxxC-dependent, active form of ADAM10, which al., 2011) by driving angiogenesis (Roca and Adams, 2007) we detect preferentially in tumors compared with normal and maintaining undifferentiated, cancer stem cells (CSCs), tissues. Moreover, the 8C7-recognized, active ADAM10 par- thought to initiate and sustain tumor growth and pro- ticularly marks CSC-like cells with high Notch activity, and mote metastasis and chemoresistance (Espinoza et al., 2013; 8C7 treatment inhibits Notch signaling and tumor growth Giancotti, 2013). However, pan-specificγ -secretase inhibi- in mouse models, particularly regrowth after chemotherapy. tors (GSIs) blocking NICD release (Groth and Fortini, 2012) cause severe intestinal toxicity, likely reflecting the diversity RES ULTS of γ-secretase targets (Dikic and Schmidt, 2010). Similarly, Preferential targeting of ADAM10 in tumors small-molecule inhibitors blocking the ADAM protease ac- We tested our anti-ADAM10 mAb 8C7 in a LIM1215 col- tive site failed clinical development, initially because of, at orectal cancer (CRC) xenograft model, which displays high Downloaded from least in part, off-target effects, reflecting the close structural levels of ADAM10, Notch, Eph, and erbB receptors. We first similarity of this site in all matrix MPs (MMPs; DasGupta et analyzed targeting to tumors and other tissues of tumor-bear- al., 2009; Saftig and Reiss, 2011). In support, more specific ing mice by injection of Alexa-labeled 8C7 and subsequent ADAM inhibitors, with limited MMP targets, show no ad- analysis of tumor and organ tissues by immunofluorescence verse effects associated with MMP inhibition, such as fibro- (IF) microscopy. Remarkably, despite 8C7 recognizing both plasias (Fridman et al., 2007). mouse and human ADAM10 (Atapattu et al., 2012), it se- The ADAM ECD contains an N-terminal pro-se- lectively bound to tumors, particularly to cells near vessels jem.rupress.org quence followed by MP (M), disintegrin (D), cysteine-rich (marked with rhodamine-lectin) and near the tumor rim, (C), transmembrane, and cytoplasmic domains (Hartmann with only slight or undetectable binding to other organs et al., 2013). Proteolytic specificity is not simply caused by (Fig. 1, A and B). In comparison, a commercial ADAM10 a typical substrate cleavage signature, but relies on noncata- antibody (MAB946) recognizing both human and mouse lytic interactions of the substrate with the ADAM C domain ADAM10 strongly stained multiple tissues (Fig. 1 B, last col- to position the substrate for effective cleavage (Smith et al., umn), consistent with the ubiquitous expression of ADAM10. on August 23, 2016 2002; Janes et al., 2005, 2009). In addition, emerging evidence We also recovered 8C7-bound ADAM10 from tumors and suggests that ADAM17 is regulated by adopting latent and organs of mice injected with 8C7, or PBS as control, by in- active ECD conformations, dependent on redox state, be- cubating protein extracts with protein A Sepharose. ADAM10 cause mild reducing or
Load more

Recommended publications
  • 3 Cleavage Products of Notch 2/Site and Myelopoiesis by Dysregulating
    ADAM10 Overexpression Shifts Lympho- and Myelopoiesis by Dysregulating Site 2/Site 3 Cleavage Products of Notch This information is current as David R. Gibb, Sheinei J. Saleem, Dae-Joong Kang, Mark of October 4, 2021. A. Subler and Daniel H. Conrad J Immunol 2011; 186:4244-4252; Prepublished online 2 March 2011; doi: 10.4049/jimmunol.1003318 http://www.jimmunol.org/content/186/7/4244 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2011/03/02/jimmunol.100331 Material 8.DC1 http://www.jimmunol.org/ References This article cites 45 articles, 16 of which you can access for free at: http://www.jimmunol.org/content/186/7/4244.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on October 4, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2011 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology ADAM10 Overexpression Shifts Lympho- and Myelopoiesis by Dysregulating Site 2/Site 3 Cleavage Products of Notch David R.
    [Show full text]
  • ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease
    International Journal of Molecular Sciences Review ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease Francesca Tosetti 1,* , Massimo Alessio 2, Alessandro Poggi 1,† and Maria Raffaella Zocchi 3,† 1 Molecular Oncology and Angiogenesis Unit, IRCCS Ospedale Policlinico S. Martino Largo R. Benzi 10, 16132 Genoa, Italy; [email protected] 2 Proteome Biochemistry, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; [email protected] 3 Division of Immunology, Transplants and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; [email protected] * Correspondence: [email protected] † These authors contributed equally to this work as last author. Abstract: Enzymes, once considered static molecular machines acting in defined spatial patterns and sites of action, move to different intra- and extracellular locations, changing their function. This topological regulation revealed a close cross-talk between proteases and signaling events involving post-translational modifications, membrane tyrosine kinase receptors and G-protein coupled recep- tors, motor proteins shuttling cargos in intracellular vesicles, and small-molecule messengers. Here, we highlight recent advances in our knowledge of regulation and function of A Disintegrin And Metalloproteinase (ADAM) endopeptidases at specific subcellular sites, or in multimolecular com- plexes, with a special focus on ADAM10, and tumor necrosis factor-α convertase (TACE/ADAM17), since these two enzymes belong to the same family, share selected substrates and bioactivity. We will discuss some examples of ADAM10 activity modulated by changing partners and subcellular compartmentalization, with the underlying hypothesis that restraining protease activity by spatial Citation: Tosetti, F.; Alessio, M.; segregation is a complex and powerful regulatory tool.
    [Show full text]
  • Cell-Autonomous FLT3L Shedding Via ADAM10 Mediates Conventional Dendritic Cell Development in Mouse Spleen
    Cell-autonomous FLT3L shedding via ADAM10 mediates conventional dendritic cell development in mouse spleen Kohei Fujitaa,b,1, Svetoslav Chakarovc,1, Tetsuro Kobayashid, Keiko Sakamotod, Benjamin Voisind, Kaibo Duanc, Taneaki Nakagawaa, Keisuke Horiuchie, Masayuki Amagaib, Florent Ginhouxc, and Keisuke Nagaod,2 aDepartment of Dentistry and Oral Surgery, Keio University School of Medicine, Tokyo 160-8582, Japan; bDepartment of Dermatology, Keio University School of Medicine, Tokyo 160-8582, Japan; cSingapore Immunology Network, Agency for Science, Technology and Research, Biopolis, 138648 Singapore; dDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892; and eDepartment of Orthopedic Surgery, National Defense Medical College, Tokorozawa 359-8513, Japan Edited by Kenneth M. Murphy, Washington University School of Medicine, St. Louis, MO, and approved June 10, 2019 (received for review November 4, 2018) Conventional dendritic cells (cDCs) derive from bone marrow (BM) intocDC1sorcDC2stakesplaceintheBM(3),andthese precursors that undergo cascades of developmental programs to pre-cDC1s and pre-cDC2s ultimately differentiate into cDC1s terminally differentiate in peripheral tissues. Pre-cDC1s and pre- and cDC2s after migrating to nonlymphoid and lymphoid tissues. + + cDC2s commit in the BM to each differentiate into CD8α /CD103 cDCs are short-lived, and their homeostatic maintenance relies + cDC1s and CD11b cDC2s, respectively. Although both cDCs rely on on constant replenishment from the BM precursors (5). The cy- the cytokine FLT3L during development, mechanisms that ensure tokine Fms-related tyrosine kinase 3 ligand (FLT3L) (12), by cDC accessibility to FLT3L have yet to be elucidated. Here, we gen- signaling through its receptor FLT3 expressed on DC precursors, erated mice that lacked a disintegrin and metalloproteinase (ADAM) is essential during the development of DCs (7, 13).
    [Show full text]
  • HCC and Cancer Mutated Genes Summarized in the Literature Gene Symbol Gene Name References*
    HCC and cancer mutated genes summarized in the literature Gene symbol Gene name References* A2M Alpha-2-macroglobulin (4) ABL1 c-abl oncogene 1, receptor tyrosine kinase (4,5,22) ACBD7 Acyl-Coenzyme A binding domain containing 7 (23) ACTL6A Actin-like 6A (4,5) ACTL6B Actin-like 6B (4) ACVR1B Activin A receptor, type IB (21,22) ACVR2A Activin A receptor, type IIA (4,21) ADAM10 ADAM metallopeptidase domain 10 (5) ADAMTS9 ADAM metallopeptidase with thrombospondin type 1 motif, 9 (4) ADCY2 Adenylate cyclase 2 (brain) (26) AJUBA Ajuba LIM protein (21) AKAP9 A kinase (PRKA) anchor protein (yotiao) 9 (4) Akt AKT serine/threonine kinase (28) AKT1 v-akt murine thymoma viral oncogene homolog 1 (5,21,22) AKT2 v-akt murine thymoma viral oncogene homolog 2 (4) ALB Albumin (4) ALK Anaplastic lymphoma receptor tyrosine kinase (22) AMPH Amphiphysin (24) ANK3 Ankyrin 3, node of Ranvier (ankyrin G) (4) ANKRD12 Ankyrin repeat domain 12 (4) ANO1 Anoctamin 1, calcium activated chloride channel (4) APC Adenomatous polyposis coli (4,5,21,22,25,28) APOB Apolipoprotein B [including Ag(x) antigen] (4) AR Androgen receptor (5,21-23) ARAP1 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1 (4) ARHGAP35 Rho GTPase activating protein 35 (21) ARID1A AT rich interactive domain 1A (SWI-like) (4,5,21,22,24,25,27,28) ARID1B AT rich interactive domain 1B (SWI1-like) (4,5,22) ARID2 AT rich interactive domain 2 (ARID, RFX-like) (4,5,22,24,25,27,28) ARID4A AT rich interactive domain 4A (RBP1-like) (28) ARID5B AT rich interactive domain 5B (MRF1-like) (21) ASPM Asp (abnormal
    [Show full text]
  • Ectodomain Shedding May Play a Pivotal Role in Disease Severity in COVID-19
    https://www.scientificarchives.com/journal/journal-of-cellular-signaling Journal of Cellular Signaling Commentary Ectodomain Shedding May Play a Pivotal Role in Disease Severity in COVID-19 Rui Yamaguchi, Yasuo Yamaguchi* Graduate School of Medical Science, Kumamoto Health Science University, Kitaku Izumi-machi 325 Kumamoto 861-5598, Japan *Correspondence should be addressed to Yasuo Yamaguchi; [email protected] Received date: April 16, 2021, Accepted date: May 21, 2021 Copyright: © 2021 Yamaguchi R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Ectodomain shedding mediated by a disintegrin and (ROS) [2]. ADAM10/7 was found to mediate ectodomain metalloprotease 10/17 (ADAM10/17) modulates the shedding to modulate immune responses [3] and to function of immune effector cells and may be involved in be activated by ROS [4]. These findings suggest that the novel coronavirus disease COVID-19. Toll-like receptor SARS-CoV-2 contributes to and induces ectodomain 7/8 (TLR7/8) recognizes single-strand RNA from viruses shedding, which may be associated with disease severity. such as severe acute respiratory syndrome coronavirus In patients with COVID-19, studies found a higher blood 2 (SARS-CoV-2, the virus that causes COVID-19) during concentration of the chemokine fractalkine [5]. Cell the innate immune response [1], and TLR7/8 agonist membrane-bound angiotensin-converting enzyme 2 activates nicotinamide adenine dinucleotide phosphate (ACE2) has been identified as a binding site and entry (NADPH) oxidase to generate reactive oxygen species receptor for the spike protein of SARS-CoV-2.
    [Show full text]
  • The Disintegrin/Metalloproteinase ADAM10 Is Essential for the Establishment of the Brain Cortex
    The Journal of Neuroscience, April 7, 2010 • 30(14):4833–4844 • 4833 Development/Plasticity/Repair The Disintegrin/Metalloproteinase ADAM10 Is Essential for the Establishment of the Brain Cortex Ellen Jorissen,1,2* Johannes Prox,3* Christian Bernreuther,4 Silvio Weber,3 Ralf Schwanbeck,3 Lutgarde Serneels,1,2 An Snellinx,1,2 Katleen Craessaerts,1,2 Amantha Thathiah,1,2 Ina Tesseur,1,2 Udo Bartsch,5 Gisela Weskamp,6 Carl P. Blobel,6 Markus Glatzel,4 Bart De Strooper,1,2 and Paul Saftig3 1Center for Human Genetics, Katholieke Universiteit Leuven and 2Department for Developmental and Molecular Genetics, Vlaams Instituut voor Biotechnologie (VIB), 3000 Leuven, Belgium, 3Institut fu¨r Biochemie, Christian-Albrechts-Universita¨t zu Kiel, D-24098 Kiel, Germany, 4Institute of Neuropathology, University Medical Center Hamburg Eppendorf, 20246 Hamburg, Germany, 5Department of Ophthalmology, University Medical Center Hamburg Eppendorf, 20246 Hamburg, Germany, and 6Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, and Departments of Medicine and of Physiology, Systems Biology and Biophysics, Weill Medical College of Cornell University, New York, New York 10021 The metalloproteinase and major amyloid precursor protein (APP) ␣-secretase candidate ADAM10 is responsible for the shedding of ,proteins important for brain development, such as cadherins, ephrins, and Notch receptors. Adam10 ؊/؊ mice die at embryonic day 9.5 due to major defects in development of somites and vasculogenesis. To investigate the function of ADAM10 in brain, we generated Adam10conditionalknock-out(cKO)miceusingaNestin-Crepromotor,limitingADAM10inactivationtoneuralprogenitorcells(NPCs) and NPC-derived neurons and glial cells. The cKO mice die perinatally with a disrupted neocortex and a severely reduced ganglionic eminence, due to precocious neuronal differentiation resulting in an early depletion of progenitor cells.
    [Show full text]
  • ADAM10 Controls Collagen Signaling and Cell Migration on Collagen by Shedding the Ectodomain of Discoidin Domain Receptor 1 (DDR1)
    M BoC | ARTICLE ADAM10 controls collagen signaling and cell migration on collagen by shedding the ectodomain of discoidin domain receptor 1 (DDR1) Yasuyuki Shitomia, Ida B. Thøgersenb, Noriko Itoa, Birgit Leitingerc, Jan J. Enghildb, and Yoshifumi Itoha aKennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7FY, United Kingdom; bDepartment of Molecular Biology and Genetics, University of Aarhus, DK-8000 Aarhus C, Denmark; cNational Heart and Lung Institute, Imperial College London, London SW7 2AZ, United Kingdom ABSTRACT Discoidin domain receptor 1 (DDR1) is a receptor tyrosine kinase that binds and Monitoring Editor transmits signals from various collagens in epithelial cells. However, how DDR1–dependent Jean E. Schwarzbauer signaling is regulated has not been understood. Here we report that collagen binding in- Princeton University duces ADAM10-dependent ectodomain shedding of DDR1. DDR1 shedding is not a result of Received: Oct 21, 2014 an activation of its signaling pathway, since DDR1 mutants defective in signaling were shed Revised: Dec 4, 2014 in an efficient manner. DDR1 and ADAM10 were found to be in a complex on the cell surface, Accepted: Dec 16, 2014 but shedding did not occur unless collagen bound to DDR1. Using a shedding-resistant DDR1 mutant, we found that ADAM10-dependent DDR1 shedding regulates the half-life of colla- gen-induced phosphorylation of the receptor. Our data also revealed that ADAM10 plays an important role in regulating DDR1-mediated cell adhesion to achieve efficient cell migration on collagen matrices. INTRODUCTION Extracellular matrix (ECM) is essential in multicellular organisms to discoidin domain receptors (DDRs), glycoprotein VI, leukocyte-asso- maintain functional tissue structures; it acts as scaffolding to support ciated, immunoglobulin-like receptors, and mannose receptors such cell migration and as a reservoir for growth factors.
    [Show full text]
  • ADAM10 and ADAM17: New Players in Trastuzumab Resistance
    www.impactjournals.com/oncotarget Oncotarget, Vol. 5, No. 22 Editorial ADAM10 and ADAM17: New Players in Trastuzumab Resistance Michael J. Duffy, John Crown and Maeve Mullooly conferring resistance to trastuzumab [6]. The availability of the anti-HER2 monoclonal Taken together, these 2 reports [2,6] suggest that antibody, trastuzumab (Herceptin) has transformed the inhibition of ADAM10, ADAM17 or preferably both outcome of a subgroup of patients with breast cancer that ADAMs is a potential new approach for minimizing previously had a poor prognosis, i.e., those with HER2- resistance to trastuzumab. Currently, several ADAM10/17 positive disease [1]. Although HER2 gene amplification/ inhibitors are available and indeed some of these have overexpression is necessary for breast cancer patients shown anti-cancer activity in preclinical systems [3,7]. to receive trastuzumab, more than 50% of patients To our knowledge, only one of these has undergone positive for this biomarker are intrinsically resistant investigations in a clinical trial, for potential anti-cancer to the treatment. Furthermore, almost all patients who activity, i.e., the dual ADAM10/17 inhibitor, INCB7839 initially respond, develop resistance which frequently (Incyte) [8]. Preliminary results suggest that this drug is occurs within the first year of treatment. Using mostly generally well tolerated with no major musculoskeletal preclinical models, several different mechanisms have side effects or anti-EGFR-related side effects such as been proposed for conferring resistance to trastuzumab. skin rash. Furthermore, there were no reports of drug- These include hyperactivation of the PI3K pathway (due induced increases in liver enzymes, bone marrow to PI3K mutations or PTEN loss), activation of alternative toxicity or increase in cardiomyopathy [8].
    [Show full text]
  • Strategies to Target ADAM17 in Disease: from Its Discovery to the Irhom Revolution
    molecules Review Strategies to Target ADAM17 in Disease: From Its Discovery to the iRhom Revolution Matteo Calligaris 1,2,†, Doretta Cuffaro 2,†, Simone Bonelli 1, Donatella Pia Spanò 3, Armando Rossello 2, Elisa Nuti 2,* and Simone Dario Scilabra 1,* 1 Proteomics Group of Fondazione Ri.MED, Research Department IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Via E. Tricomi 5, 90145 Palermo, Italy; [email protected] (M.C.); [email protected] (S.B.) 2 Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy; [email protected] (D.C.); [email protected] (A.R.) 3 Università degli Studi di Palermo, STEBICEF (Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche), Viale delle Scienze Ed. 16, 90128 Palermo, Italy; [email protected] * Correspondence: [email protected] (E.N.); [email protected] (S.D.S.) † These authors contributed equally to this work. Abstract: For decades, disintegrin and metalloproteinase 17 (ADAM17) has been the object of deep investigation. Since its discovery as the tumor necrosis factor convertase, it has been considered a major drug target, especially in the context of inflammatory diseases and cancer. Nevertheless, the development of drugs targeting ADAM17 has been harder than expected. This has generally been due to its multifunctionality, with over 80 different transmembrane proteins other than tumor necrosis factor α (TNF) being released by ADAM17, and its structural similarity to other metalloproteinases. This review provides an overview of the different roles of ADAM17 in disease and the effects of its ablation in a number of in vivo models of pathological conditions.
    [Show full text]
  • Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases
    Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases Alan J. Barrett Neil D. Rawlings J. Fred Woessner Editor biographies xxi Contributors xxiii Preface xxxi Introduction ' Abbreviations xxxvii ASPARTIC PEPTIDASES Introduction 1 Aspartic peptidases and their clans 3 2 Catalytic pathway of aspartic peptidases 12 Clan AA Family Al 3 Pepsin A 19 4 Pepsin B 28 5 Chymosin 29 6 Cathepsin E 33 7 Gastricsin 38 8 Cathepsin D 43 9 Napsin A 52 10 Renin 54 11 Mouse submandibular renin 62 12 Memapsin 1 64 13 Memapsin 2 66 14 Plasmepsins 70 15 Plasmepsin II 73 16 Tick heme-binding aspartic proteinase 76 17 Phytepsin 77 18 Nepenthesin 85 19 Saccharopepsin 87 20 Neurosporapepsin 90 21 Acrocylindropepsin 9 1 22 Aspergillopepsin I 92 23 Penicillopepsin 99 24 Endothiapepsin 104 25 Rhizopuspepsin 108 26 Mucorpepsin 11 1 27 Polyporopepsin 113 28 Candidapepsin 115 29 Candiparapsin 120 30 Canditropsin 123 31 Syncephapepsin 125 32 Barrierpepsin 126 33 Yapsin 1 128 34 Yapsin 2 132 35 Yapsin A 133 36 Pregnancy-associated glycoproteins 135 37 Pepsin F 137 38 Rhodotorulapepsin 139 39 Cladosporopepsin 140 40 Pycnoporopepsin 141 Family A2 and others 41 Human immunodeficiency virus 1 retropepsin 144 42 Human immunodeficiency virus 2 retropepsin 154 43 Simian immunodeficiency virus retropepsin 158 44 Equine infectious anemia virus retropepsin 160 45 Rous sarcoma virus retropepsin and avian myeloblastosis virus retropepsin 163 46 Human T-cell leukemia virus type I (HTLV-I) retropepsin 166 47 Bovine leukemia virus retropepsin 169 48
    [Show full text]
  • Proteolytic Cleavage—Mechanisms, Function
    Review Cite This: Chem. Rev. 2018, 118, 1137−1168 pubs.acs.org/CR Proteolytic CleavageMechanisms, Function, and “Omic” Approaches for a Near-Ubiquitous Posttranslational Modification Theo Klein,†,⊥ Ulrich Eckhard,†,§ Antoine Dufour,†,¶ Nestor Solis,† and Christopher M. Overall*,†,‡ † ‡ Life Sciences Institute, Department of Oral Biological and Medical Sciences, and Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada ABSTRACT: Proteases enzymatically hydrolyze peptide bonds in substrate proteins, resulting in a widespread, irreversible posttranslational modification of the protein’s structure and biological function. Often regarded as a mere degradative mechanism in destruction of proteins or turnover in maintaining physiological homeostasis, recent research in the field of degradomics has led to the recognition of two main yet unexpected concepts. First, that targeted, limited proteolytic cleavage events by a wide repertoire of proteases are pivotal regulators of most, if not all, physiological and pathological processes. Second, an unexpected in vivo abundance of stable cleaved proteins revealed pervasive, functionally relevant protein processing in normal and diseased tissuefrom 40 to 70% of proteins also occur in vivo as distinct stable proteoforms with undocumented N- or C- termini, meaning these proteoforms are stable functional cleavage products, most with unknown functional implications. In this Review, we discuss the structural biology aspects and mechanisms
    [Show full text]
  • Insulin Stimulates the Cleavage and Release of the Extracellular Domain of Klotho by ADAM10 and ADAM17
    Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17 Ci-Di Chen*, Sonia Podvin†, Earl Gillespie†, Susan E. Leeman†‡, and Carmela R. Abraham*‡§ Departments of *Biochemistry, †Pharmacology, and §Medicine, Boston University School of Medicine, Boston, MA 02118 Contributed by Susan E. Leeman, October 16, 2007 (sent for review July 25, 2007) Cleavage and release (shedding) of membrane proteins is a critical (6, 7), and serine proteases (8). ADAMs are particularly important regulatory step in many normal and pathological processes. Evi- for ectodomain shedding of proteins such as Notch, the amyloid-␤ dence suggests that the antiaging transmembrane protein Klotho precursor protein (APP), and TGF-␣, which, as a result of shed- (KL) is shed from the cell surface by proteolytic cleavage. In this ding, transactivate surface receptors in autocrine or paracrine study, we attempted to identify the enzymes responsible for the mechanisms (9–11). shedding of KL by treating KL-transfected COS-7 cells with a panel In this study, we searched for the sheddase responsible for KL of proteinase inhibitors and measuring cleavage products by West- ectodomain shedding from the cell membrane in KL-transfected ern blot. We report that metalloproteinase inhibitors, including COS-7 cells by examining a panel of putative inhibitors, including EDTA, EGTA, and TAPI-1, inhibit the shedding of KL, whereas insulin. We selected insulin because it is a substrate and a compet- insulin increases shedding. The effects of the inhibitors in KL- itive inhibitor of insulin degrading enzyme (IDE), and KL has been transfected COS-7 cells were repeated in studies on rat kidney reported to be involved in the inhibition of the insulin signaling slices ex vivo, which validates the use of COS-7 cells as our model pathway (2).
    [Show full text]